Accumulating evidence suggests that a high tumour burden has a negative effect on
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …

Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to
immunotherapy. BR. 36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

Despite advances in screening and therapeutics cancer continues to be one of the major
causes of morbidity and mortality worldwide. The molecular profile of tumor is routinely …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

Background Melanoma lacks validated blood-based biomarkers for monitoring and
predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising …

The optimal duration of therapy in patients receiving immune-checkpoint inhibitors (ICIs) is a
new but crucial question that has arisen owing to the observation of durable remissions in> …

Skin cancer is, at present, the most common type of malignancy in the Caucasian
population. Its incidence has increased rapidly in the last decade for both melanoma and …

Purpose: We evaluated the predictive value of pretreatment ctDNA to inform therapeutic
outcomes in patients with metastatic melanoma relative to type and line of treatment …